These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22302783)

  • 1. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.
    Rapkin L; Qayed M; Brill P; Martin M; Clark D; George BA; Olson TA; Wasilewski-Masker K; Alazraki A; Katzenstein HM
    Pediatr Blood Cancer; 2012 Nov; 59(5):854-8. PubMed ID: 22302783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
    Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
    Mora J; Cruz CO; Parareda A; de Torres C
    J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.
    Kuo C; Kent PM; Logan AD; Tamulonis KB; Dalton KL; Batus M; Fernandez K; Mcfall RE
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
    Metts JL; Alazraki AL; Clark D; Amankwah EK; Wasilewski-Masker KJ; George BA; Olson TA; Cash T
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27246. PubMed ID: 29770997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
    Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
    Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
    Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y
    Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
    Lee EM; Rha SY; Lee J; Park KH; Ahn JH
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
    Navid F; Willert JR; McCarville MB; Furman W; Watkins A; Roberts W; Daw NC
    Cancer; 2008 Jul; 113(2):419-25. PubMed ID: 18484657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
    Palmerini E; Jones RL; Marchesi E; Paioli A; Cesari M; Longhi A; Meazza C; Coccoli L; Fagioli F; Asaftei S; Grignani G; Tamburini A; Pollack SM; Picci P; Ferrari S
    BMC Cancer; 2016 Apr; 16():280. PubMed ID: 27098543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
    Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
    Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.
    Song BS; Seo J; Kim DH; Lim JS; Yoo JY; Lee JA
    Pediatr Blood Cancer; 2014 Aug; 61(8):1376-81. PubMed ID: 24692087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
    Bay JO; Ray-Coquard I; Fayette J; Leyvraz S; Cherix S; Piperno-Neumann S; Chevreau C; Isambert N; Brain E; Emile G; Le Cesne A; Cioffi A; Kwiatkowski F; Coindre JM; Bui NB; Peyrade F; Penel N; Blay JY;
    Int J Cancer; 2006 Aug; 119(3):706-11. PubMed ID: 16496406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
    Tansir G; Rastogi S; Kumar A; Barwad A; Mridha AR; Dhamija E; Shamim SA; Bhatnagar S; Bhoriwal S
    BMC Cancer; 2023 Jul; 23(1):639. PubMed ID: 37422615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
    Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y
    World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
    Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
    BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
    Ebeling P; Eisele L; Schuett P; Bauer S; Schuette J; Moritz T; Seeber S; Flasshove M
    Onkologie; 2008 Feb; 31(1-2):11-6. PubMed ID: 18268394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
    He A; Qi W; Huang Y; Sun Y; Shen Z; Zhao H; Yang Y; Yao Y
    Int J Clin Oncol; 2013 Jun; 18(3):498-505. PubMed ID: 22534798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
    Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C
    PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
    Hingorani P; Eshun F; White-Collins A; Watanabe M
    J Pediatr Hematol Oncol; 2012 Oct; 34(7):524-7. PubMed ID: 23007339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.